Dicerna Pharmaceuticals Inc (DRNA) Receives $21.31 Consensus Target Price from Analysts
Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) have been assigned an average rating of “Buy” from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.31.
A number of research firms have recently weighed in on DRNA. Leerink Swann began coverage on Dicerna Pharmaceuticals in a research note on Tuesday, November 27th. They set an “outperform” rating and a $24.00 price target for the company. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. B. Riley raised Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $13.50 to $21.00 in a research note on Tuesday, November 6th. Cowen reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, November 6th. Finally, HC Wainwright raised their price target on Dicerna Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, October 31st.
In other news, Director Brian K. Halak sold 245,096 shares of the stock in a transaction dated Tuesday, October 30th. The stock was sold at an average price of $13.92, for a total transaction of $3,411,736.32. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Brian K. Halak sold 335,000 shares of the stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $13.33, for a total value of $4,465,550.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,144,396 shares of company stock worth $15,585,624. 19.85% of the stock is currently owned by insiders.
DRNA opened at $13.60 on Monday. Dicerna Pharmaceuticals has a fifty-two week low of $6.80 and a fifty-two week high of $17.98. The stock has a market cap of $870.72 million, a PE ratio of -3.72 and a beta of 2.39.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.11). Dicerna Pharmaceuticals had a negative return on equity of 63.24% and a negative net margin of 1,418.01%. The firm had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.67 million. As a group, equities research analysts anticipate that Dicerna Pharmaceuticals will post -1.15 earnings per share for the current fiscal year.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Read More: Market Capitalization
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.